Our products - Giving new hope to patients with key therapeutic solutions

Tools content (print, share, increase/decrease text size):

 

Our websites

 

Middle area:

Oncology

Scott, cancer, USA

Sanofi’s mission is to create solutions for currently unmet medical needs. Sanofi employ innovative approaches to attack cancer on all fronts and provide medicines adapted to the diverse profiles of patients.

 

Through its acquisitions and targeted partnerships, Sanofi is carrying out research on newly discovered aspects of cancer development, growth and progression.

Sanofi is a key actor in the field of oncology, particularly in chemotherapy, with three major products:

  • The taxoid Taxotere® is a cornerstone of treatment for several types of cancer and is available in more than 100 countries (1).
  • The platinum-based agent Eloxatine® is a major treatment in colorectal cancer and is available in more than 70 countries (1).
  • Jevtana® is a new taxane derivative resulting from 14 years of research and development. Jevtana is now approved in 78 countries (1).
  • Mozobil® (plerixafor injection) is a hematopoietic stem cell mobilizer indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM).
  • Zaltrap® (aflibercept) is a recombinant fusion protein which acts as a soluble decoy receptor that binds to Vascular Endothelial Growth Factor-A (VEGF-A), VEGF-B and placental growth factor (PIGF), preventing the bound VEGF from binding to their native receptors. VEGF-A is one of the mediators contributing to angiogenesis. VEGF-B and PlGF, related growth factors in the VEGF family, may contribute to tumor angiogenesis as well. In the U.S, Zaltrap® is a registered trademark of Regeneron Pharmaceuticals, Inc.

The oncology R&D portfolio comprises a large range of new anticancer treatments with different mechanisms of action. These include in particular cytotoxic, antimitotic, and antiangiogenic agents, as well as targeted therapies and monoclonal antibodies.

To help patients and their loved-ones understand and manage the disease, Sanofi collaborates with numerous patient support associations worldwide through its affiliates.

 
 

1. For more information, please consult the Summaries of Product Characteristics for the products available in your country.

 

Right area:

Further information

Partners

 

Research and Development

 

© Sanofi 2004-2014 - All rights reserved - Update: January 16, 2014